Arbelaez F

No ORCID on file · 4 papers in corpus
2026
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of Linustedastat (OG-6219) in Women with Moderate to Severe Endometriosis-Related Pain

Felipe Arbelaez,1 Julia Yureneva,2 Per Larsson,3 Daniela Colaci,1 Keith Gordon,4 Leon Dupclay,5 Krzysztof Wilk61Department of Global Clinical Research, Organon, Jersey, NJ, USA; 2Department of Drug Safety, Organon, Jersey, NJ, USA; 3Departm…

other 2026
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of Linustedastat (OG-6219) in Women with Moderate to Severe Endometriosis-Related Pain
International journal of women's health ·doi:10.2147/IJWH.S622776

PURPOSE: Endometriosis causes pelvic pain, dysmenorrhea (DYS), dyspareunia, and fertility issues. Linustedastat (OG-6219) is an oral, selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (HSD17β1), an enzyme involved in local estr…

rct 2025
Randomized, controlled, proof-of-concept trial of gefapixant for endometriosis-related pain
Fertility and sterility ·doi:10.1016/j.fertnstert.2024.09.013

OBJECTIVE: To evaluate the P2X3 receptor antagonist, gefapixant, for treating moderate-to-severe endometriosis-related pain. DESIGN: Randomized, double-blind, phase 2, and proof-of-concept trial. SUBJECTS: Premenopausal women age 18-49 ye…

other 2022
The endometriosis daily diary: qualitative research to explore the patient experience of endometriosis and inform the development of a patient-reported outcome (PRO) for endometriosis-related pain
Journal of patient-reported outcomes ·doi:10.1186/s41687-021-00409-8

PURPOSE: Endometriosis is a chronic disorder of the female reproductive system characterized by debilitating symptoms, particularly endometriosis-related pain (ERP). Patient-reported outcome (PRO) measures of symptoms and impacts are requir…